CO2024001524A2 - Degradadores bifuncionales de quinasas asociadas al receptor de interleucina 1 y usos terapéuticos de los mismos - Google Patents
Degradadores bifuncionales de quinasas asociadas al receptor de interleucina 1 y usos terapéuticos de los mismosInfo
- Publication number
- CO2024001524A2 CO2024001524A2 CONC2024/0001524A CO2024001524A CO2024001524A2 CO 2024001524 A2 CO2024001524 A2 CO 2024001524A2 CO 2024001524 A CO2024001524 A CO 2024001524A CO 2024001524 A2 CO2024001524 A2 CO 2024001524A2
- Authority
- CO
- Colombia
- Prior art keywords
- interleukin
- receptor
- therapeutic uses
- associated kinases
- degraders
- Prior art date
Links
- 230000001588 bifunctional effect Effects 0.000 title abstract 2
- 239000001064 degrader Substances 0.000 title abstract 2
- 102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 title 1
- 108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 abstract 2
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 abstract 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 abstract 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 abstract 1
- 102000044159 Ubiquitin Human genes 0.000 abstract 1
- 108090000848 Ubiquitin Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163234606P | 2021-08-18 | 2021-08-18 | |
| PCT/US2022/040765 WO2023023255A1 (en) | 2021-08-18 | 2022-08-18 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024001524A2 true CO2024001524A2 (es) | 2024-02-26 |
Family
ID=83594510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0001524A CO2024001524A2 (es) | 2021-08-18 | 2024-02-14 | Degradadores bifuncionales de quinasas asociadas al receptor de interleucina 1 y usos terapéuticos de los mismos |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11976071B2 (https=) |
| EP (2) | EP4512402A3 (https=) |
| JP (2) | JP7774709B2 (https=) |
| KR (1) | KR20240048010A (https=) |
| CN (1) | CN117813307A (https=) |
| AR (1) | AR126826A1 (https=) |
| AU (2) | AU2022330009B2 (https=) |
| CA (1) | CA3226118A1 (https=) |
| CL (1) | CL2024000446A1 (https=) |
| CO (1) | CO2024001524A2 (https=) |
| CR (1) | CR20240080A (https=) |
| DK (1) | DK4367118T3 (https=) |
| DO (1) | DOP2024000028A (https=) |
| ES (1) | ES3024057T3 (https=) |
| FI (1) | FI4367118T3 (https=) |
| HR (1) | HRP20250402T1 (https=) |
| HU (1) | HUE070709T2 (https=) |
| IL (1) | IL310446A (https=) |
| LT (1) | LT4367118T (https=) |
| MX (1) | MX2024002153A (https=) |
| PE (1) | PE20241618A1 (https=) |
| PL (1) | PL4367118T3 (https=) |
| PT (1) | PT4367118T (https=) |
| SI (1) | SI4367118T1 (https=) |
| TW (2) | TW202535879A (https=) |
| WO (1) | WO2023023255A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021026517A2 (pt) | 2019-06-28 | 2022-05-10 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| US12551564B2 (en) | 2019-12-10 | 2026-02-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021127190A1 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP4107158A1 (en) | 2020-02-19 | 2022-12-28 | Nurix Therapeutics, Inc. | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof |
| US20240208923A1 (en) | 2021-03-10 | 2024-06-27 | Jnana Therapeutics Inc. | Small molecule inhibitors of mammalian slc6a19 function |
| FI4367118T3 (fi) | 2021-08-18 | 2025-04-09 | Nurix Therapeutics Inc | Interleukiini-1-reseptoriin liittyvien kinaasien bifunktionaalisia hajotusaineita ja niiden terapeuttinen käyttö |
| WO2023186069A1 (zh) * | 2022-03-31 | 2023-10-05 | 石药集团中奇制药技术（石家庄）有限公司 | 一类白介素-1受体相关激酶4的双功能嵌合体杂环化合物及其制备方法、药用组合物和用途 |
| KR20260022390A (ko) | 2023-06-08 | 2026-02-19 | 누릭스 테라퓨틱스 인코포레이티드 | Smarca2의 선택적 분해제로서의 이작용성 아진 접합체 및 이의 치료적 용도 |
| WO2025149070A1 (zh) * | 2024-01-10 | 2025-07-17 | 甘李药业股份有限公司 | 一种新型靶向白细胞介素1受体关联激酶4(irak4)的蛋白降解嵌合体化合物的合成及其应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
| US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| US7041298B2 (en) | 2000-09-08 | 2006-05-09 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| US7030112B2 (en) | 2003-03-25 | 2006-04-18 | Bristol-Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
| CA2663091A1 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Modulators of interleukin-1 receptor-associated kinase |
| US9464326B2 (en) | 2012-03-22 | 2016-10-11 | University Of Maryland, Baltimore | Total and phosphorylated IL-1 receptor-associated kinase-1 and IL-1 receptor-associated kinase-4 as a biomarker for cancer progression and chemotherapy resistance |
| TW201609693A (zh) | 2014-01-03 | 2016-03-16 | 必治妥美雅史谷比公司 | 雜芳基取代之菸鹼醯胺化合物 |
| AU2015247817C1 (en) | 2014-04-14 | 2022-02-10 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| TW201718571A (zh) | 2015-06-24 | 2017-06-01 | 必治妥美雅史谷比公司 | 經雜芳基取代之胺基吡啶化合物 |
| ES2822956T3 (es) | 2015-06-24 | 2021-05-05 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituidos con heteroarilo |
| US10487329B2 (en) | 2015-10-29 | 2019-11-26 | Children's Hospital Medical Center | Methods and compositions for the treatment of head and neck cancer |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| WO2018071606A1 (en) | 2016-10-11 | 2018-04-19 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| EP3532164A4 (en) | 2016-10-28 | 2020-10-07 | Children's Hospital Medical Center | TREATMENT OF IRAQ ASSOCIATED DISEASES ACTIVATED |
| BR112019015484A2 (pt) | 2017-01-31 | 2020-04-28 | Arvinas Operations Inc | ligantes de cereblon e compostos bifuncionais compreendendo os mesmos |
| TW202340194A (zh) | 2017-02-16 | 2023-10-16 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| WO2018232288A1 (en) | 2017-06-16 | 2018-12-20 | Genentech, Inc. | Diagnostic and therapeutic methods for irak4-mediated disorders and conditions |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| WO2019103196A1 (ko) | 2017-11-24 | 2019-05-31 | 엘지전자 주식회사 | 무선 통신 시스템에서 빔을 리포팅하는 방법 및 장치 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019160915A1 (en) | 2018-02-14 | 2019-08-22 | Dana-Farber Cancer Institute, Inc. | Irak degraders and uses thereof |
| TWI842978B (zh) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| US20200038513A1 (en) | 2018-07-26 | 2020-02-06 | Arvinas Operations, Inc. | Modulators of fak proteolysis and associated methods of use |
| WO2020036830A1 (en) | 2018-08-13 | 2020-02-20 | Gilead Sciences, Inc. | Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors |
| TWI727392B (zh) | 2018-08-13 | 2021-05-11 | 美商基利科學股份有限公司 | 噻二唑irak4抑制劑 |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP4038066A1 (en) | 2019-10-01 | 2022-08-10 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| US11820781B2 (en) * | 2019-12-04 | 2023-11-21 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| EP4107158A1 (en) * | 2020-02-19 | 2022-12-28 | Nurix Therapeutics, Inc. | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof |
| WO2021180103A1 (en) | 2020-03-11 | 2021-09-16 | Beigene, Ltd. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| MX2022016061A (es) | 2020-06-17 | 2023-02-02 | Kymera Therapeutics Inc | Degradadores de cinasa asociada al receptor interleucina-1 (irak) y usos de los mismos. |
| WO2021255212A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Braf degraders |
| US20240208923A1 (en) | 2021-03-10 | 2024-06-27 | Jnana Therapeutics Inc. | Small molecule inhibitors of mammalian slc6a19 function |
| CA3217892A1 (en) | 2021-05-03 | 2022-11-10 | Joel Mcintosh | Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use |
| US12018016B2 (en) | 2021-08-18 | 2024-06-25 | Amgen Inc. | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors |
| FI4367118T3 (fi) | 2021-08-18 | 2025-04-09 | Nurix Therapeutics Inc | Interleukiini-1-reseptoriin liittyvien kinaasien bifunktionaalisia hajotusaineita ja niiden terapeuttinen käyttö |
| TW202321229A (zh) | 2021-08-18 | 2023-06-01 | 美商富曼西公司 | 殺真菌的取代的雜環化合物 |
-
2022
- 2022-08-18 FI FIEP22785813.1T patent/FI4367118T3/fi active
- 2022-08-18 PL PL22785813.1T patent/PL4367118T3/pl unknown
- 2022-08-18 CN CN202280056402.6A patent/CN117813307A/zh active Pending
- 2022-08-18 TW TW114118091A patent/TW202535879A/zh unknown
- 2022-08-18 ES ES22785813T patent/ES3024057T3/es active Active
- 2022-08-18 JP JP2024508943A patent/JP7774709B2/ja active Active
- 2022-08-18 LT LTEPPCT/US2022/040765T patent/LT4367118T/lt unknown
- 2022-08-18 AR ARP220102235A patent/AR126826A1/es unknown
- 2022-08-18 EP EP25150164.9A patent/EP4512402A3/en active Pending
- 2022-08-18 US US17/820,770 patent/US11976071B2/en active Active
- 2022-08-18 CA CA3226118A patent/CA3226118A1/en active Pending
- 2022-08-18 KR KR1020247008466A patent/KR20240048010A/ko active Pending
- 2022-08-18 HU HUE22785813A patent/HUE070709T2/hu unknown
- 2022-08-18 EP EP22785813.1A patent/EP4367118B1/en active Active
- 2022-08-18 IL IL310446A patent/IL310446A/en unknown
- 2022-08-18 CR CR20240080A patent/CR20240080A/es unknown
- 2022-08-18 PE PE2024000254A patent/PE20241618A1/es unknown
- 2022-08-18 SI SI202230111T patent/SI4367118T1/sl unknown
- 2022-08-18 WO PCT/US2022/040765 patent/WO2023023255A1/en not_active Ceased
- 2022-08-18 AU AU2022330009A patent/AU2022330009B2/en active Active
- 2022-08-18 MX MX2024002153A patent/MX2024002153A/es unknown
- 2022-08-18 PT PT227858131T patent/PT4367118T/pt unknown
- 2022-08-18 TW TW111131116A patent/TWI886406B/zh active
- 2022-08-18 DK DK22785813.1T patent/DK4367118T3/da active
- 2022-08-18 HR HRP20250402TT patent/HRP20250402T1/hr unknown
-
2024
- 2024-02-14 CL CL2024000446A patent/CL2024000446A1/es unknown
- 2024-02-14 DO DO2024000028A patent/DOP2024000028A/es unknown
- 2024-02-14 CO CONC2024/0001524A patent/CO2024001524A2/es unknown
- 2024-04-01 US US18/623,738 patent/US12570662B2/en active Active
-
2025
- 2025-02-14 JP JP2025022773A patent/JP7820584B2/ja active Active
- 2025-09-23 AU AU2025234314A patent/AU2025234314A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024001524A2 (es) | Degradadores bifuncionales de quinasas asociadas al receptor de interleucina 1 y usos terapéuticos de los mismos | |
| MX2025000271A (es) | Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades | |
| CO2022013414A2 (es) | Degradadores de mdm2 y usos de los mismos | |
| CL2020002839A1 (es) | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas. | |
| CO2019011873A2 (es) | Compuestos de heteroarilo bicíclicos 6–6 fusionados y su uso como inhibidores de lats | |
| CO2021006672A2 (es) | Moduladores de nlrp3 | |
| CL2022000093A1 (es) | Imidazopirimidinas como inhibidores de eed y uso de estas | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| UY28333A1 (es) | Inhibidores de caspasa y sus usos. | |
| PY21110949A (es) | Macrociclos y sus usos | |
| CL2022001887A1 (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas | |
| MX2022002532A (es) | Métodos para generar y aislar neuronas de dopamina del mesencéfalo. | |
| CO2021011919A2 (es) | Derivados de tieno[3,2-b] pirrol[3,2-d]piridazinona y uso de estos como derivados de pkm2 para el tratamiento del cáncer, la obesidad y trastornos relacionados con la diabetes | |
| DOP2025000213A (es) | [1,3]tiazolo[4,5-d]-pirimidin-7-onas como inhibidores de la nox4 | |
| AR054786A1 (es) | (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1 | |
| CL2024000340A1 (es) | Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades | |
| CL2021002521A1 (es) | Compuestos heteocíclicos y sus usos. | |
| MX2024005431A (es) | Degradadores bifuncionales de la cinasa progenitora hematopoyética y sus usos terapéuticos. | |
| CL2025003186A1 (es) | Moduladores de nk3 y usos de los mismos. | |
| CO2025016647A2 (es) | Inhibidores de egfr para el tratamiento de enfermedades | |
| MX2021012872A (es) | Polipeptidos multiespecificos terapeuticos activados mediante intercambio de cadenas polipeptidicas. | |
| CO2022002022A2 (es) | Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias | |
| CL2024001748A1 (es) | Usos de compuestos biciclicos para el tratamiento de enfermedades. | |
| MX2025001164A (es) | Inhibidores de calicreina plasmatica. | |
| UY40788A (es) | Compuestos para el tratamiento de trastornos neurológicos |